LSE:STX - Shield Therapeutics - ACCRUFeR® assigned Priority Review in US by FDA

About Us

Overview Leadership Contact and Locations

Medicines

Portfolio Approved Medicine ID/IDA Facts and Figures Publications

Investor

Investor Overview Stock Information Financials Analysts & Advisors AIM Rule 26 Corporate Governance My Account

News & Media

News Webinars Media

Shield Therapeutics - ACCRUFeR® assigned Priority Review in US by FDA

Your question will be visible to everyone.

Start the conversation

Ask Shield Therapeutics a question about this announcement.

Share your feedback

Discover